news

Announcements and Updates


Virometix Appoints Dr. Pierre A. Morgon as New Chairman and Dr. Isaac Kobrin as New Member of the Board of Virometix AG

Virometix Appoints Dr. Pierre A. Morgon as New Chairman and Dr. Isaac Kobrin as New Member of the Board of Virometix AG

SourcePress Release

CompanyVirometix 

TagsPersonnel

DateJanuary 25, 2017

Emmanuel Savioz nominated as new Chief Financial Officer and Prof. Paul-Henri Lambert appointed as Scientific Advisory Board member

Schlieren, Switzerland  (25.01.2017) –  Virometix  today announced the appointment of Dr.  Pierre  A. Morgon, PharmD, LL.M., MBA as Chairman and Dr. Isaac Kobrin as independent member to its Board of Directors. In addition, the company announced the nomination of Emmanuel Savioz, MBA as new Chief Financial Officer. With these appointments  Virometix  is taking further steps to enhance professional expertise within the Board of Directors and senior management of the company. Furthermore, the Scientific Advisory Board has been strengthened with the addition of emeritus Prof. Paul-Henri Lambert, MD.

Dr. Pierre  Morgon is a doctor of pharmacy and MBA holder with additional qualifications in Business Law. He has over 30 years experience up to C-level positions in large life science companies, including  Sanofi  Pasteur , and biotech firms such  as AJ-Biologics. In these roles, he has provided leadership in the construction and expansion of vaccine portfolios and partnerships, with turnaround initiatives and with financing for start-up vaccine companies. Dr. Morgon is also Regional Partner for  Switzerland  at Mérieux Développement, Non-Executive Director to the Board of  Theradiag , as well as Non-Executive Director to the Board of Eurocine Vaccines .

Dr. Morgon stated: “I am thrilled to join Virometix  at a pivotal phase where we will strive to demonstrate the value of the company’s broad proprietary technology, both in the field of vaccines and in cancer immunotherapy.”

Dr. Isaac Kobrin, MD is an internist with 15 years experience in academic medicine both in Israel and the USA. With 23 years of experience in the Pharma industry, he was responsible for the worldwide clinical development of key compounds at Roche  for 10 years and subsequently in  Actelion  for 13 years. In  Actelion , Dr. Kobrin was the head of clinical development and member of the executive committee for 10 years and later he was appointed as Chief Medical Officer and Chairman of the Strategic and Portfolio Board of the company. During the last 4 years, Dr. Kobrin has been supporting several Pharma and biotechnology companies as a Board member and/or as an advisor.

Emmanuel Savioz, MBA has 15 years experience in financing and business. He co-founded and is a Board member of several high tech companies in Switzerland  including Phi Pharma, HYT, and Preciflex. Over the past 7 years, Mr. Savioz arranged more than CHF 70 million of equity financing for high tech companies in  Switzerland . Previously, he worked in New York as an investment banker in M&A handling large international transactions in consumer goods and healthcare. Emmanuel Savioz is former member of the Admission Committee of the MBA Program at IMD  in Lausanne,  Switzerland , and holds an MBA from the Haas School of Business, University of California at Berkeley , USA.

Prof. Paul -Henri Lambert, MD, is now associated with the Centre of Vaccinology in the Department of Pathology  and Immunology at University of Geneva. He is directing the International Advanced Course of Vaccinology (ADVAC) organized under the auspices of the Fondation Mérieux and University of Geneva. He is a member of the Governing Board of the  Tuberculosis Vaccine  Initiative (TBVI), past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the Global Advisory Committee on Vaccine Safety of the World Health Organization (WHO). In 1987, he was appointed as chief of Microbiology and Immunology at the World Health Organization and in 1994, chief of the Vaccine Research and Development, WHO Global Program for Vaccines and Immunization. During this time he was deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries.

“We are delighted to have some highly respected people like Dr. Morgon, Dr. Kobrin, Mr. Savioz and Prof. Lambert with their background and expertise come on board”, said Dr. Arin Ghasparian, CEO of Virometix . “They will be a perfect fit for us, as we are progressing very well with the development of our vaccine products, our scientific research and in discussions on future partnerships.”

Isaac KobrinVirometix AG